The U.S. Food and Drug Administration (FDA) has released the draft guidance “Q3E Guideline for Extractables and Leachables,” now open for public and stakeholder comments until 30 January 2026.
This draft guideline introduces a comprehensive, globally aligned framework for assessing extractables and leachables (E&Ls) in pharmaceutical products, biologics, and combination medical products. Developed in collaboration with the International Council for Harmonisation (ICH), the document aims to ensure consistency, scientific rigor, and enhanced patient safety across the industry.
Key areas covered in the draft include:
✔️ Systematic approach for identifying and evaluating extractables and leachables
✔️ Recommended analytical methods for E&L studies across development stages
✔️ Toxicological risk assessment principles to support safety evaluations
✔️ Documentation and reporting expectations for regulatory submissions
✔️ Lifecycle considerations, ensuring continued control of E&Ls from development to commercial production
Once finalized, this guideline will represent the FDA’s current regulatory expectations for E&L assessment, supporting safer and higher-quality drug products.
📄 Download Draft Guidance:
https://www.fda.gov/media/189890/download
#Q3E #Extractables #Leachables #Toxicology #Pharma #Biopharma #MedicalDevices #RiskAssessment #QualityControl #RegulatoryAffairs #ICH #FDA #PatientSafety
